Please Wait
Applying Filters...
menu
    • menu
    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

    Virtual Booth

    Contact Supplier

    Boai NKY Pharmaceuticals Ltd. is one of the largest global PVP suppliers.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-06-09

    Virtual Booth

    An Enquiry

    Menu

    Teprotumumab

    DEVELOPMENTS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Amgen's Tepezza Granted Marketing Authorisation in UK
    Amgen's Tepezza Granted Marketing Authorisation in UK

    07 May 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250507246547/en/Amgens-TEPEZZA-teprotumumab-Granted-Marketing-Authorisation-as-the-First-Targeted-Treatment-Specifically-for-Adults-With-Moderate-to-severe-Thyroid-Eye-Disease-TED-in-the-United-Kingdom

    BUSINESSWIRE
    07 May 2025
    Share Share
    Innovent's SYCUME® Approved by NMPA for Thyroid Eye Disease
    Innovent's SYCUME® Approved by NMPA for Thyroid Eye Disease

    14 Mar 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/chinas-first-igf-1r-monoclonal-antibody-innovent-announces-nmpa-approval-of-sycume-for-the-treatment-of-thyroid-eye-disease-302401791.html

    PR NEWSWIRE
    14 Mar 2025
    Share Share
    Amgen 1Q Results
    Amgen 1Q Results

    21 May 2024

    // CONTRACT PHARMA

    https://www.contractpharma.com/contents/view_breaking-news/2024-05-21/amgen-1q-results/?widget=listSection

    CONTRACT PHARMA
    21 May 2024
    Share Share
    AMGEN to Submit Teprotumumab MAA to EMA
    AMGEN to Submit Teprotumumab MAA to EMA

    26 Apr 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/amgen-to-submit-teprotumumab-marketing-authorization-application-to-the-european-medicines-agency-302128358.html

    PR NEWSWIRE
    26 Apr 2024
    Share Share
    Amgen reports 3rd straight sequential sales increase for Tepezza
    Amgen reports 3rd straight sequential sales increase for Tepezza

    07 Feb 2024

    // Kevin Dunleavy FIERCE PHARMA

    https://www.fiercepharma.com/pharma/amgen-expects-revenue-bump-its-acquisition-horizon-between-324b-and-338b

    Kevin Dunleavy FIERCE PHARMA
    07 Feb 2024
    Share Share
    Analysis Highlights Adhering to Uninterrupted Full Course with TEPEZZA
    Analysis Highlights Adhering to Uninterrupted Full Course with TEPEZZA

    29 Sep 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230929700356/en

    BUSINESSWIRE
    29 Sep 2023
    Share Share